US officials insist PrEP research 'imperative,' despite halted Truvada study in women
This article was originally published in Scrip
Executive Summary
Just six months after researchers revealed stunningly positive results in a study testing a pre-exposure prophylactic (PrEP) dose of Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) in preventing HIV infection in gay men, another trial testing the drug in women, known as FEM-PrEP, was prematurely halted after an independent data monitoring committee determined efficacy was highly unlikely to be reached, even if the study continued to its originally planned conclusion.